ARS Net Debt vs Net Receivables Analysis

SPRY Stock

16.97 0.53 3.03%

ARS Pharmaceuticals, financial indicator trend analysis is way more than just evaluating ARS Pharmaceuticals, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ARS Pharmaceuticals, is a good investment. Please check the relationship between ARS Pharmaceuticals, Net Debt and its Net Receivables accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in ARS Pharmaceuticals,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy ARS Stock please use our How to Invest in ARS Pharmaceuticals, guide.

Net Debt vs Net Receivables

Net Debt vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ARS Pharmaceuticals, Net Debt account and Net Receivables. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between ARS Pharmaceuticals,'s Net Debt and Net Receivables is -0.18. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Net Receivables in the same time period over historical financial statements of ARS Pharmaceuticals,, assuming nothing else is changed. The correlation between historical values of ARS Pharmaceuticals,'s Net Debt and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of ARS Pharmaceuticals, are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Net Debt i.e., ARS Pharmaceuticals,'s Net Debt and Net Receivables go up and down completely randomly.

Correlation Coefficient

-0.18

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Net Receivables

Most indicators from ARS Pharmaceuticals,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ARS Pharmaceuticals, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in ARS Pharmaceuticals,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy ARS Stock please use our How to Invest in ARS Pharmaceuticals, guide.At this time, ARS Pharmaceuticals,'s Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 1,489 in 2025, whereas Tax Provision is likely to drop slightly above 158.4 K in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	36.8M	67.6M	91.3M	95.8M
Cost Of Revenue	17.3M	73K	977K	928.2K

Total Operating Expenses Cost Of Revenue

ARS Pharmaceuticals, fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Other Liab	Net Tangible Assets	Current Deferred Revenue	Non Currrent Assets Other	Other Assets	Long Term Debt	Net Receivables
Total Assets		-0.88	0.85	0.61	0.97	-0.68	-0.65	-0.9	0.78	0.65	0.55	1.0	0.77	0.53	0.94	0.9	0.57	1.0	-0.64	-0.97	0.99	-0.9	0.24	0.99	-0.88	0.82
Short Long Term Debt Total	-0.88		-0.62	-0.22	-0.91	0.48	0.65	0.76	-0.49	-0.63	-0.45	-0.88	-0.72	-0.3	-0.76	-0.83	-0.3	-0.88	0.89	0.82	-0.89	0.81	-0.27	-0.89	0.76	-0.63
Other Current Liab	0.85	-0.62		0.89	0.73	-0.47	-0.24	-0.74	0.99	0.25	0.83	0.81	0.64	0.7	0.96	0.59	0.78	0.83	-0.41	-0.81	0.78	-0.59	0.26	0.78	-0.66	0.99
Total Current Liabilities	0.61	-0.22	0.89		0.46	-0.4	-0.01	-0.57	0.95	0.05	0.72	0.58	0.44	0.69	0.78	0.36	0.79	0.6	0.01	-0.6	0.53	-0.37	0.16	0.54	-0.47	0.86
Total Stockholder Equity	0.97	-0.91	0.73	0.46		-0.58	-0.71	-0.9	0.64	0.71	0.48	0.97	0.77	0.3	0.85	0.91	0.35	0.97	-0.65	-0.9	0.99	-0.87	0.38	0.99	-0.81	0.71
Property Plant And Equipment Net	-0.68	0.48	-0.47	-0.4	-0.58		0.6	0.57	-0.46	-0.6	0.09	-0.7	-0.54	-0.64	-0.61	-0.76	-0.62	-0.69	0.43	0.76	-0.66	0.8	0.24	-0.67	0.81	-0.42
Net Debt	-0.65	0.65	-0.24	-0.01	-0.71	0.6		0.45	-0.15	-1.0	0.07	-0.69	-0.28	-0.12	-0.38	-0.75	-0.11	-0.67	0.51	0.63	-0.67	0.76	0.01	-0.67	0.69	-0.18
Retained Earnings	-0.9	0.76	-0.74	-0.57	-0.9	0.57	0.45		-0.7	-0.44	-0.48	-0.9	-0.9	-0.38	-0.84	-0.87	-0.44	-0.9	0.44	0.89	-0.93	0.86	-0.25	-0.93	0.81	-0.72
Accounts Payable	0.78	-0.49	0.99	0.95	0.64	-0.46	-0.15	-0.7		0.18	0.81	0.75	0.59	0.73	0.92	0.52	0.81	0.77	-0.27	-0.76	0.71	-0.53	0.21	0.71	-0.62	0.97
Cash	0.65	-0.63	0.25	0.05	0.71	-0.6	-1.0	-0.44	0.18		-0.06	0.69	0.25	0.15	0.39	0.73	0.13	0.67	-0.48	-0.64	0.66	-0.75	-0.02	0.67	-0.69	0.19
Non Current Assets Total	0.55	-0.45	0.83	0.72	0.48	0.09	0.07	-0.48	0.81	-0.06		0.5	0.4	0.39	0.71	0.22	0.47	0.52	-0.27	-0.46	0.49	-0.19	0.46	0.48	-0.25	0.86
Cash And Short Term Investments	1.0	-0.88	0.81	0.58	0.97	-0.7	-0.69	-0.9	0.75	0.69	0.5		0.77	0.51	0.92	0.92	0.55	1.0	-0.64	-0.97	0.99	-0.92	0.22	0.99	-0.89	0.79
Common Stock Shares Outstanding	0.77	-0.72	0.64	0.44	0.77	-0.54	-0.28	-0.9	0.59	0.25	0.4	0.77		0.34	0.77	0.84	0.38	0.77	-0.52	-0.76	0.81	-0.75	0.27	0.81	-0.71	0.65
Non Current Liabilities Total	0.53	-0.3	0.7	0.69	0.3	-0.64	-0.12	-0.38	0.73	0.15	0.39	0.51	0.34		0.65	0.37	0.99	0.52	-0.32	-0.66	0.4	-0.5	-0.45	0.42	-0.67	0.68
Other Current Assets	0.94	-0.76	0.96	0.78	0.85	-0.61	-0.38	-0.84	0.92	0.39	0.71	0.92	0.77	0.65		0.76	0.71	0.93	-0.58	-0.9	0.9	-0.73	0.3	0.9	-0.76	0.96
Other Stockholder Equity	0.9	-0.83	0.59	0.36	0.91	-0.76	-0.75	-0.87	0.52	0.73	0.22	0.92	0.84	0.37	0.76		0.39	0.91	-0.62	-0.9	0.93	-0.95	0.13	0.93	-0.9	0.56
Total Liab	0.57	-0.3	0.78	0.79	0.35	-0.62	-0.11	-0.44	0.81	0.13	0.47	0.55	0.38	0.99	0.71	0.39		0.57	-0.27	-0.68	0.45	-0.5	-0.35	0.47	-0.66	0.75
Total Current Assets	1.0	-0.88	0.83	0.6	0.97	-0.69	-0.67	-0.9	0.77	0.67	0.52	1.0	0.77	0.52	0.93	0.91	0.57		-0.64	-0.97	0.99	-0.91	0.22	0.99	-0.89	0.81
Short Term Debt	-0.64	0.89	-0.41	0.01	-0.65	0.43	0.51	0.44	-0.27	-0.48	-0.27	-0.64	-0.52	-0.32	-0.58	-0.62	-0.27	-0.64		0.61	-0.63	0.6	-0.13	-0.63	0.57	-0.46
Other Liab	-0.97	0.82	-0.81	-0.6	-0.9	0.76	0.63	0.89	-0.76	-0.64	-0.46	-0.97	-0.76	-0.66	-0.9	-0.9	-0.68	-0.97	0.61		-0.94	0.95	0.0	-0.95	0.96	-0.78
Net Tangible Assets	0.99	-0.89	0.78	0.53	0.99	-0.66	-0.67	-0.93	0.71	0.66	0.49	0.99	0.81	0.4	0.9	0.93	0.45	0.99	-0.63	-0.94		-0.9	0.32	1.0	-0.85	0.76
Current Deferred Revenue	-0.9	0.81	-0.59	-0.37	-0.87	0.8	0.76	0.86	-0.53	-0.75	-0.19	-0.92	-0.75	-0.5	-0.73	-0.95	-0.5	-0.91	0.6	0.95	-0.9		0.1	-0.91	0.98	-0.55
Non Currrent Assets Other	0.24	-0.27	0.26	0.16	0.38	0.24	0.01	-0.25	0.21	-0.02	0.46	0.22	0.27	-0.45	0.3	0.13	-0.35	0.22	-0.13	0.0	0.32	0.1		0.29	0.22	0.3
Other Assets	0.99	-0.89	0.78	0.54	0.99	-0.67	-0.67	-0.93	0.71	0.67	0.48	0.99	0.81	0.42	0.9	0.93	0.47	0.99	-0.63	-0.95	1.0	-0.91	0.29		-0.86	0.76
Long Term Debt	-0.88	0.76	-0.66	-0.47	-0.81	0.81	0.69	0.81	-0.62	-0.69	-0.25	-0.89	-0.71	-0.67	-0.76	-0.9	-0.66	-0.89	0.57	0.96	-0.85	0.98	0.22	-0.86		-0.62
Net Receivables	0.82	-0.63	0.99	0.86	0.71	-0.42	-0.18	-0.72	0.97	0.19	0.86	0.79	0.65	0.68	0.96	0.56	0.75	0.81	-0.46	-0.78	0.76	-0.55	0.3	0.76	-0.62

Click cells to compare fundamentals

ARS Pharmaceuticals, Account Relationship Matchups

ARS Pharmaceuticals, fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	26.4M	61.4M	281.4M	233.2M	351.2M	368.7M
Short Long Term Debt Total	10.0M	9.0M	481K	274K	42K	39.9K
Other Current Liab	915K	1.3M	2.9M	1.4M	13.0M	13.6M
Total Current Liabilities	8.2M	8.2M	5.4M	2.4M	23.4M	24.6M
Total Stockholder Equity	(14.1M)	(31.3M)	272.9M	230.8M	256.8M	269.6M
Property Plant And Equipment Net	23K	693K	774K	824K	1.1M	1.6M
Net Debt	(14.5M)	(51.0M)	(210.0M)	(70.7M)	(50.8M)	(53.3M)
Retained Earnings	(22.0M)	(42.3M)	(76.9M)	(131.3M)	(123.3M)	(117.1M)
Accounts Payable	1.2M	1.8M	1.7M	759K	9.9M	10.4M
Cash	24.5M	60.1M	210.5M	71.0M	50.8M	70.2M
Non Current Assets Total	25K	716K	3.7M	1.5M	16.9M	17.7M
Cash And Short Term Investments	24.5M	60.1M	274.4M	228.4M	314.0M	329.7M
Common Stock Shares Outstanding	34.7M	28.9M	40.0M	95.2M	102.4M	57.7M
Liabilities And Stockholders Equity	26.4M	61.4M	281.4M	233.2M	351.2M	368.7M
Non Current Liabilities Total	32.2M	84.5M	3.1M	37K	70.9M	74.5M
Other Current Assets	1.5M	666K	2.3M	2.6M	5.9M	6.2M
Other Stockholder Equity	50.2M	87.0M	349.4M	362.0M	379.9M	194.6M
Total Liab	40.5M	92.7M	8.5M	2.4M	94.4M	99.1M
Total Current Assets	26.4M	60.7M	277.7M	231.7M	334.3M	351.0M
Short Term Debt	2.6M	3.6M	460K	237K	42K	39.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
V	Visa Class A
GOOG	Alphabet Inc Class C

Additional Tools for ARS Stock Analysis

When running ARS Pharmaceuticals,'s price analysis, check to measure ARS Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals, is operating at the current time. Most of ARS Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

ARS Net Debt vs Net Receivables Analysis

Net Debt vs Net Receivables

Net Debt vs Net Receivables Correlation Analysis

Correlation Coefficient

Net Debt

Net Receivables

ARS Pharmaceuticals, fundamental ratios Correlations

ARS Pharmaceuticals, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ARS Pharmaceuticals, fundamental ratios Accounts

Also Currently Popular

Additional Tools for ARS Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Assets	+ 1.0	Net Tangible Assets
Net Tangible Assets	+ 0.99	Total Assets
Other Assets	+ 0.99	Total Assets

Cash	- 1.0	Net Debt
Other Liab	- 0.97	Total Current Assets
Other Liab	- 0.97	Cash And Short Term Investments
Other Liab	- 0.97	Total Assets
Other Assets	- 0.95	Other Liab
Current Deferred Revenue	- 0.95	Other Stockholder Equity